Navigation Links
Cadence Pharmaceuticals Reports Third Quarter 2013 Financial Results
Date:11/5/2013

e months ending December 31, 2013. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Cadence's actual future results may differ materially from Cadence's current expectations due to the risks and uncertainties inherent in its business. These risks include, but are not limited to: Cadence's dependence on the successful commercialization of OFIRMEV, which is the company's only product; Cadence's ability to achieve broad market acceptance and generate revenues from sales of OFIRMEV; Cadence's dependence on its contract manufacturers and its ability to ensure an adequate and continued supply of OFIRMEV to meet market demand; Cadence's ability to successfully enforce its marketing exclusivities and intellectual property rights, and to defend the patents covering OFIRMEV, including in current intellectual property litigation with the parties that have submitted new drug applications ("NDAs") or abbreviated new drug applications ("ANDAs") for generic versions of OFIRMEV; the potential that Cadence may be required to continue intellectual property litigation for substantial lengths of time or file additional lawsuits to defend its patent rights from challenges by companies that have submitted NDAs or ANDAs for generic versions of OFIRMEV, and the substantial costs associated with such lawsuits; the potential introduction of generic competition to OFIRMEV in the event Cadence is unsuccessful in current or future intellectual property litigation, and the impact it may have on the sales and pricing of the product; Cadence's dependence on its licensors for the maintenance and enforcement of its intellectual property rights; the potential product liability exposure associated with pharmaceutical products such as OFIRMEV and other products Cadence may in-license or acquire; Cadence's ability to fully comply with numerous federal, state and local laws and regulatory requirements that apply to its commercial a
'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2013 Financial Results On November 5, 2013
2. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Stifel Nicolaus Healthcare Conference 2013 On September 11, 2013
3. Cadence Pharmaceuticals Comments on USPTOs Non-Final, Initial Office Action on Reexamination of Patent
4. Cadence Pharmaceuticals Appoints Laureen DeBuono to its Board of Directors
5. Cadence Pharmaceuticals To Present At The 2013 Wedbush PacGrow Life Sciences Management Access Conference On August 13, 2013
6. Cadence Pharmaceuticals Reports Second Quarter 2013 Financial Results
7. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Second Quarter 2013 Financial Results On July 31, 2013
8. Cadence Pharmaceuticals To Present At Three Investment Conferences During The Month Of May 2013
9. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss First Quarter 2013 Financial Results On May 2, 2013
10. Cadence Pharmaceuticals Appoints Stephen L. Newman, M.D., to its Board of Directors
11. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... HAMBURG, Germany , Aug. 21, 2014 /PRNewswire/ ... collaborating with Deutsches Elektronen-Synchrotron ( DESY ), a leading ... to speed up management and storage of massive volumes ... Analytics architecture based on IBM software defined technology ... data at peak performance and help scientists worldwide gain ...
(Date:8/21/2014)... Aug. 21, 2014  ACI Clinical ( www.aciclinical.com ... Data Monitoring Committees. Using this solution, ... over industry standard costs and receive the same ... in committee services. Leveraging a decade ... contracting, charter development, statistical programming and meeting facilitation), ...
(Date:8/21/2014)... Aug. 21, 2014 CVS Caremark Corporation (NYSE: ... Reference Yields and consideration payable in connection with its previously ... 7, 2014 for (1) any and all of its 6.250% ... (2) up to a maximum amount of its 6.125% Senior ... Senior Notes due 2017 (collectively, the "Maximum Tender Offer Notes" ...
Breaking Medicine Technology:DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3ACI Clinical: Innovation and Savings in Data Safety Monitoring Committees 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6
... EAST BRUNSWICK, N.J., Nov. 3, 2011 Savient Pharmaceuticals, Inc. ... the three and nine months ended September 30, 2011, which ... KRYSTEXXA® (pegloticase). Savient ended the quarter with $202.7 million in ... the quarter.  For the third quarter of 2011, the Company ...
... LOS ANGELES, Nov. 3, 2011 MedInformatix, a ... industry, announced today it has completed certification with ... certification, the MedInformatixVersion 7.5 prescriber software connected through ... exchange prescription information electronically through the Surescripts secure ...
Cached Medicine Technology:Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 2Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 3Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 4Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 5Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 6Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 7MedInformatix Earns Surescripts® Prescription Routing Certification 2MedInformatix Earns Surescripts® Prescription Routing Certification 3
(Date:8/21/2014)... NC -- Researchers have pinpointed the environmental source of ... Southern California for decades. It literally grows on trees. ... of a 13-year-old girl, who spent the summer gathering ... hardest hit by infections of the fungus named ... Cryptococcus , which encompasses a number of species including ...
(Date:8/21/2014)... 21, 2014 (HealthDay News) -- Being born at a low ... 2 diabetes, a new study suggests. The findings may ... that has a high prevalence of low birth weight, the ... women found that those with a low birth weight were ... those with a normal birth weight. The risk of diabetes ...
(Date:8/21/2014)... A new study published this week in the ... with speech problems from 2001-02 to 2010-11 among U.S. ... disability associated with hearing problems. The data underscore the ... who are experiencing communication disorders, according to the ... broader level, the new study, Changing Trends of ...
(Date:8/21/2014)... Hollywood, FL (PRWEB) August 21, 2014 ... being published today in The Journal of the American ... significantly more invasive cancers and reduces unnecessary recalls. Memorial ... participate in the study. , “This study confirms what ... the invasive, harmful cancers we want to find and, ...
(Date:8/21/2014)... According to a new market report published ... - Home Theatre in-a-box, Home audio systems, Home radios, ... Size, Share, Growth, Trends and Forecast, 2013 - 2019,” ... 2012 and is expected to reach USD 20.68 billion ... 2013 to 2019. Europe was the largest contributor to ...
Breaking Medicine News(10 mins):Health News:Fungus deadly to AIDS patients found to grow on trees 2Health News:Low Birth Weights May Put Black Women at Risk for Diabetes 2Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 2Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 3Health News:Dr. Mary Hayes: Study Shows 3D Mammography Finds More Invasive Cancers While Reducing Unnecessary Recalls 2Health News:Home Audio Equipment Market Expected to Reach USD 20.68 Billion in 2019 2Health News:Home Audio Equipment Market Expected to Reach USD 20.68 Billion in 2019 3
... therapy to significantly improve overall survival in patients with ... 20 Bayer HealthCare Pharmaceuticals and Onyx ... that the Ministry of Health, Labour and Welfare (MHLW) ... treatment of patients with unresectable hepatocellular carcinoma (HCC), a ...
... Recondo Technology, a leading provider of revenue cycle ... Harry Gambill and Jeff Fritz have joined the ... Gambill began with TransUnion in 1985 and served ... During his 16-year tenure, TransUnion grew from a ...
... high schoolers take to the stage at the House of Blues ... creative seat belt messagesCLEVELAND, May 20 Local teens had a ... at the House of Blues at noon on Tuesday, May 19, ... It High School Seat Belt Challenge, sponsored by Kohl,s, wrapped ...
... C. Mendell and Lloyd H. Malchow Join Digirad Board ... DRAD ) today announced that it has ... H. Malchow to its Board of Directors, effective immediately. ... board to a total of seven members."Steve and Lloyd ...
... 403(b) market are pushing nonprofit clients to eliminate options for participants by ... with 403(b)connect, now is the time to keep provider and investment choices ... ... 2009 -- The new fully automated 403(b)connect by se2 is ...
... CoSign® digital signatures fully integrate with Adobe LiveCycle® ES, decreasing costs ... , ... San Francisco, CA (PRWEB) May 20, 2009 -- ... the CoSign digital signature (standard electronic signature) solution , and ...
Cached Medicine News:Health News:Nexavar Approved in Japan for the Treatment of Advanced Liver Cancer 2Health News:Nexavar Approved in Japan for the Treatment of Advanced Liver Cancer 3Health News:Nexavar Approved in Japan for the Treatment of Advanced Liver Cancer 4Health News:Nexavar Approved in Japan for the Treatment of Advanced Liver Cancer 5Health News:Nexavar Approved in Japan for the Treatment of Advanced Liver Cancer 6Health News:Recondo Technology Announces Two New Board Members 2Health News:Rainbow Babies & Children's Hospital's Use It or Lose It High School Seat Belt Challenge Brings Out the Creativity in Cuyahoga County Teens 2Health News:Rainbow Babies & Children's Hospital's Use It or Lose It High School Seat Belt Challenge Brings Out the Creativity in Cuyahoga County Teens 3Health News:Digirad Names Two Veteran Healthcare Executives to Board 2Health News:Digirad Names Two Veteran Healthcare Executives to Board 3Health News:Digirad Names Two Veteran Healthcare Executives to Board 4Health News:403(b) Administration Now Turn-Key with New 'Single Solution/Multi-Provider' Web Hosted Platform - 403(b)connect 2Health News:403(b) Administration Now Turn-Key with New 'Single Solution/Multi-Provider' Web Hosted Platform - 403(b)connect 3Health News:SAFE-BioPharma Webinar Featuring ARX's Digital Signature Solution and Adobe LiveCycle Combined Solution 2Health News:SAFE-BioPharma Webinar Featuring ARX's Digital Signature Solution and Adobe LiveCycle Combined Solution 3
This free-standing work station safely ventilates fumes upwards, away from the work surface. Optional Exhaust Purification System features bonded charcoal filters that remove organic chemical vapors ...
... is the same as model ... flat internal baffle across the ... baffle slopes forward, leaving space ... sweep the deck and space ...
... The Benchtop Fume Hood is an ... installations in which a number of fume ... schools, junior colleges and universities. Features include ... polyethylene with rounded inside corners for easy ...
This is the second generation of the famous A/O sliding microtome, manufactured in the United States under the Leica trademark....
Medicine Products: